Helicobacter pylori–related metabolic syndrome as predictor of progression to esophageal carcinoma in a subpopulation-based Barrett's esophagus cohort

Gastrointestinal Endoscopy

Volumn 85, Issue 2, 2017, Pages 462-463

  Kountouras, Jannis ^a   Polyzos, Stergios A ^a   Zeglinas, Christos ^a   Tzathas, Charalampos ^a   Nikolaidis, Nikos ^a   Vardaka, Elizabeth ^a   Kountouras, Constantinos ^a   Anastadiadis, Sotiris ^a   Anastasiadis, Kyriaki ^a   Giorgakis, Nikolaos ^a   Gavalas, Emmanouel ^a   Tzivras, Dimitri ^a   Katsinelos, Panagiotis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; BARRETT ESOPHAGUS; CAMPYLOBACTER; CANCER GROWTH; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; LETTER; METABOLIC SYNDROME X; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; ADENOCARCINOMA; ESOPHAGUS TUMOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METABOLIC SYNDROME X;

EID: 85009212188     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2016.07.017     Document Type: Letter

References (10)

1. 1 Krishnamoorthi, R., Borah, B., Heien, H., et al. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc 84 (2016), 40–46.
2. 2 Polyzos, S.A., Kountouras, J., Novel advances in the association between Helicobacter pylori infection, metabolic syndrome, and related morbidity. Helicobacter 20 (2015), 405–409.
3. 3 Zhang, N., Huan, Y., Huang, H., et al. Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate. Acta Pharmacol Sin 31 (2010), 35–42.
4. 4 Kountouras, J., Chatzopoulos, D., Zavos, C., et al. Helicobacter pylori infection might contribute to esophageal adenocarcinoma progress in subpopulations with gastroesophageal reflux disease and Barrett's esophagus. Helicobacter 17 (2012), 402–403.
5. 5 Kountouras, J., Chatzopoulos, D., Zavos, C., Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus. Med Hypotheses 68 (2007), 1174–1175.
6. 6 Kountouras, Zavos, C., Polyzos, S.A., et al. Helicobacter pylori infection and gastroesophageal reflux disease: Barrett's esophagus sequence “dilemma.”. Ann Gastroenterol, 28, 2015, 153.
7. 7 Mozaffari Namin, B., Soltan Dallal, M.M., Ebrahimi Daryani, N., The effect of Campylobacter concisus on expression of IL-18, TNF-α and p53 in Barrett's cell lines. Jundishapur J Microbiol, 8, 2015, e26393.
8. 8 Kountouras, J., Zavos, C., Chatzopoulos, D., et al. Helicobacter pylori and gastro-oesophageal reflux disease. Lancet, 368, 2006, 986.
9. 9 Polyzos, S.A., Kountouras, J., Zavos, C., et al. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 16 (2011), 79–88.
10. 10 Franceschi, F., Gasbarrini, A., Polyzos, S.A., et al. Extragastric diseases and Helicobacter pylori. Helicobacter 20 (2016), 40–46.